What is Jumpcode Genomics?
Jumpcode Genomics is at the forefront of enhancing the utility of next-generation sequencing (NGS) data for the research community. The company offers a suite of advanced products, including programmable endonuclease enzymes and various depletion kits. These solutions are specifically designed to improve critical areas of genomic research such as single-cell analysis, microbiome characterization, infectious disease detection, and whole transcriptome profiling. Jumpcode Genomics primarily serves academic institutions and researchers dedicated to genomics and molecular biology, aiming to convert raw sequenced molecules into actionable data through their innovative technologies.
How much funding has Jumpcode Genomics raised?
Jumpcode Genomics has raised a total of $24.5M across 2 funding rounds:
Series A
$3.5M
Series B
$21M
Series A (2018): $3.5M, investors not publicly disclosed
Series B (2021): $21M led by LYZZ Capital Advisors, Arboretum Ventures LLC, and Baird Capital
Key Investors in Jumpcode Genomics
LYZZ Capital Advisors
LYZZ Capital Advisors is an entity involved in the recent funding round for Jumpcode Genomics. Further details on their investment focus are not publicly available.
Arboretum Ventures LLC
Arboretum Ventures LLC participated in Jumpcode Genomics' recent financing. Their specific investment thesis or sector specialization is not detailed in the provided information.
Baird Capital
Baird Capital is a private equity and venture capital firm that invests in founder-led B2B tech and services companies globally. They manage two distinct investment strategies: Global Private Equity and Venture Capital, focusing on sectors where they possess deep institutional knowledge. The firm emphasizes a partnership approach with management teams, providing operational support and expertise to foster growth. Baird Capital is recognized for its strong culture and commitment to collaboration, making it a preferred partner for entrepreneurs and businesses seeking to scale.
What's next for Jumpcode Genomics?
The recent major strategic investment in Jumpcode Genomics signals a pivotal moment for the company, likely enabling accelerated development and commercialization of its advanced NGS data enhancement tools. This capital infusion is expected to fuel expansion into new markets and deepen its research collaborations. With a focus on improving single-cell analysis and other critical genomic applications, Jumpcode Genomics is well-positioned to capitalize on the growing demand for sophisticated molecular biology solutions, further solidifying its role as a key player in the genomics technology landscape.
See full Jumpcode Genomics company page
